ALT:NSD-Altimmune Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.26

Change

0.00 (0.00)%

Market Cap

USD 0.49B

Volume

1.58M

Avg Analyst Target

USD 25.50 (+126.47%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ALT Stock Forecast & Price:
Based on the Altimmune Inc stock forecasts from 3 analysts, the average analyst target price for Altimmune Inc is USD 25.50 over the next 12 months. Altimmune Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Altimmune Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Altimmune Inc’s stock price was USD 11.26. Altimmune Inc’s stock price has changed by -4.17% over the past week, +106.99% over the past month and +20.56% over the last year.

About Altimmune Inc (ALT:NSD)

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b ...Read More

Company Website : https://altimmune.com

Address : 910 Clopper Road, Gaithersburg, MD, United States, 20878

Employees : 47

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.43

52 Week High : 17.26

Short Ratio : 4.13

52 Week Low : 3.83

Shorted Shares : 6,157,132

200 Day Moving Average : 8.46

Shorted Shares Previous Month : 3,942,676

50 Day Moving Average : 6.41

Shares Held By Insiders : 5.95%

Short Percentage : 16.05%

Shares Held by Institutions : 82.45%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

 USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

N/A

 USD65.40B 8.39 6.52
MRNA Moderna Inc

N/A

 USD59.64B 4.20 2.94
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD38.28B 2.86 1.54
SGEN Seagen Inc

N/A

 USD33.15B 55.02 -50.53
RPRX Royalty Pharma Plc

N/A

 USD28.81B 29.89 16.26
GMAB Genmab AS

N/A

 USD21.88B 64.29 5.76
ARGX argenx NV ADR

N/A

 USD20.61B N/A -30.89
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ALT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.93% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.93% 95% A 97% A+
Trailing 12 Months  
Capital Gain 20.56% 96% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.56% 96% A 94% A
Trailing 5 Years  
Capital Gain -88.20% 27% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.20% 27% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain 105.07% 91% A- 95% A
Dividend Return 40.30% 100% A+ 100% A+
Total Return 145.37% 93% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 296.35% 7% F 4% F
Risk Adjusted Return 49.05% 87% B+ 79% C+
Market Capitalization 0.49B 73% C 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.82 67% D+ 91% A-
Price/Book Ratio 2.75 38% F 32% F
Price / Cash Flow Ratio -6.22 72% C- 74% C
EV/EBITDA -3.26 75% C 76% C
Management Effectiveness  
Return on Equity -47.14% 60% D- 24% F
Return on Invested Capital -45.26% 59% F 22% F
Return on Assets -24.51% 55% F 17% F
Debt to Equity Ratio 0.73% 85% B 87% B+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.13 56% F 42% F
Short Percent 16.05% 10% F 11% F
Beta 1.43 47% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector